Journal of Clinical Lipidology
Volume 2, Issue 6 , Pages 418-425 , December 2008

Rosuvastatin reduces non–high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia)

  • Dirk J. Blom, PhD

      Affiliations

    • Lipidology Division of Internal Medicine, Groote Schuur Hospital and University of Cape Town, Lipid Laboratory, 5th Floor, Christiaan Barnard Building, UCT Faculty of Health Sciences, Anzio Road, 7925 Observatory Cape Town, South Africa
    • Corresponding Author InformationCorresponding author
    • ,
  • A. David Marais, MD

      Affiliations

    • Lipidology Division of Internal Medicine, Groote Schuur Hospital and University of Cape Town, Lipid Laboratory, 5th Floor, Christiaan Barnard Building, UCT Faculty of Health Sciences, Anzio Road, 7925 Observatory Cape Town, South Africa
    • ,
  • Kjetil Retterstøl, MD

      Affiliations

    • Lipid Clinic, Rikshospitalet, Oslo, Norway
    • ,
  • Evan A. Stein, MD

      Affiliations

    • Metabolic & Atherosclerosis Research Center, Cincinnati, OH, USA
    • ,
  • Joseph Ycas, PhD

      Affiliations

    • AstraZeneca, Wilmington, DE, USA
    • ,
  • Zheng Gu, MD

      Affiliations

    • AstraZeneca, Wilmington, DE, USA
    • ,
  • Elinor Miller, MD

      Affiliations

    • AstraZeneca, Wilmington, DE, USA

Received 7 July 2008 ,Accepted 19 October 2008.

References 

  1. Blom DJ, Byrnes P, Jones S, Marais AD. Dysbetalipoproteinaemia—clinical and pathophysiological features. S Afr Med J. 2002;92:892–897
  2. Brewer HB, Zech LA, Gregg RE, Schwartz D, Schaefer EJ. NIH conference (Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment). Ann Intern Med. 1983;98:623–640
  3. Feussner G, Wagner A, Kohl B, Ziegler R. Clinical features of type III hyperlipoproteinemia: analysis of 64 patients. Clin Investig. 1993;71:362–366
  4. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1–16
  5. Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med. 1975;82:158–174
  6. Smelt AH, de Beer F. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. Semin Vasc Med. 2004;4:249–257
  7. Le NA, Walter MF. The role of hypertriglyceridemia in atherosclerosis. Curr Atheroscler Rep. 2007;9:110–115
  8. Nakamura T, Kugiyama K. Triglycerides and remnant particles as risk factors for coronary artery disease. Curr Atheroscler Rep. 2006;8:107–110
  9. Walden CC, Hegele RA. Apolipoprotein E in hyperlipidemia. Ann Intern Med. 1994;120:1026–1036
  10. de Villiers WJ, van der Westhuyzen DR, Coetzee GA, Henderson HE, Marais AD. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. Arterioscler Thromb Vasc Biol. 1997;17:865–872
  11. Mahley RW, Huang Y, Rall SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia) (Questions, quandaries, and paradoxes). J Lipid Res. 1999;40:1933–1949
  12. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  13. Leary ET, Wang T, Baker DJ, et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem. 1998;44:2490–2498
  14. Civeira F, Cenarro A, Ferrando J, et al. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am Heart J. 1999;138:156–162
  15. Feussner G, Eichinger M, Ziegler R. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. Clin Investig. 1992;70:1027–1035
  16. Illingworth DR, O'Malley JP. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism. 1990;39:403–409
  17. Knopp RH, Illingworth DR, Stein EA, et al. Effect of pravastatin in the treatment of patients with type III hyperlipoproteinemia. Am J Ther. 1996;3:755–762
  18. van Dam M, Zwart M, de Beer F, et al. Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart. 2002;88:234–238
  19. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003;92:1287–1293

PII: S1933-2874(08)00888-X

doi: 10.1016/j.jacl.2008.10.002

Journal of Clinical Lipidology
Volume 2, Issue 6 , Pages 418-425 , December 2008

Article Tools

* Image Usage & Resolution